| Abbott posts latest financial results | Posted on 15/10/2009 in Pharmaceutical Company Financials Abbott has unveiled its financial results for the third quarter of the year, posting earnings growth of 16.5 per cent.
It reported an increase of 8.4 per cent in its worldwide operational sales, a 16.2 per cent rise in its medical products operational sales and growth of 15.2 per cent in international pharmaceutical sales.
The company has also raised its earnings-per-share outlook for 2009.
Furthermore, Abbott completed several acquisitions during the timeframe, namely those of pharmaceutical firm Solvay, cardiac mitral valves manufacturer Evalve and intraocular lens supplier Visiogen.
Miles White, chairman and chief executive officer of the company, commented: "These acquisitions add to our diverse mix of global businesses, with new technologies, established products and emerging market infrastructure that will help us deliver sustainable industry-leading growth."
The firm's financial details come after its AKI diagnosis kit - designed for those with suspected acute kidney injury - received the CE mark last week.
Other news stories from 15/10/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
